

Gregory W. Daniel, PhD, MPH, RPh

Location: Washington, DC
Phone: 202.615.0318
Email: gdaniel@brookings.edu

EXECUTIVE PROFILE

Accomplished, results-driven, and detail-oriented executive leader in health policy and research. Executive level success at forming, managing, and growing new lines of research business, setting departmental goals and strategic vision, business development, and fostering multi-organizational collaborations. Seasoned health care researcher with expertise in pharmaceutical and health policy, regulatory science, convening expert thought leaders, and leading large observational research studies in the areas of health economics and outcomes research, comparative effectiveness research, pharmacoepidemiology and drug safety evaluations. Strong statistical, analytic and methodology skills and significant experience utilizing electronic health care data including administrative claims, laboratory results, registries, and electronic medical records to generate medical evidence that informs healthcare decision making and the delivery of care.

PROFESSIONAL EXPERIENCE

The Brookings Institution, Washington, DC

11/2011 – present

Fellow, Economic Studies

Managing Director, Center for Health Care Reform

Oversee and provide strategic direction regarding the Center for Health Care Policy's evidence development and biomedical innovation portfolio that aims to develop practical policy solutions for critical areas of health reform, including pharmaceutical and medical device innovation, regulatory science and FDA policy, and policies for development of research infrastructure to improve medical evidence generation, including drug and device safety surveillance and comparative effectiveness research. Provide leadership, management, and mentorship to a team of researchers, lead convening activities that contribute enhancing biomedical innovation and enabling better medical evidence generation to support decision-making across the health care setting. Other responsibilities include overseeing all content development and logistics in carrying out policy roundtables, workgroups with partner organizations and other events associated with evidence development and innovation activities; advising the Center director on all policy, research, and management matters relating to evidence development and biomedical innovation; coordinating with other fellows throughout the Center to develop cohesive and practical policy solutions that will help support effective implementation of health care reform; and identifying new business development opportunities.

Specific initiatives and topics include:

- Pharmaceutical and medical device economics, payment policy, and reforms
 - Prescription Drug User Fee Act (PDUFA) implementation, policy reforms for patient-reported outcome instrument and biomarker development and qualification
 - Regulatory science and expedited drug development and review tools such as Breakthrough designation and special medical use
 - FDA Sentinel Initiative
 - PCORI's PCORnet- The National Patient-Centered Clinical Research Network
 - Implementation of the Unique Device Identifiers for post-market evaluation of device safety and effectiveness
 - Centers for Medicare & Medicaid Services' Coverage with Evidence Development (CED)
-

The Reagan-Udall Foundation for the Food and Drug Administration, Washington, DC

9/2012 – present

Sr. Advisor for the Innovation in Medical Evidence and Surveillance (IMEDS) Program

Provide strategic and technical expertise and oversight to the development of the governance, business strategy, grant strategy, and operating model for the IMEDS Program. This program is a public-private partnership that aims to advance the mission of the FDA by directing and facilitating methods research to improve the knowledge and tools for using electronic health data for safety surveillance and effectiveness research; provides fellowship and educational opportunities to train new scientists; and explores opportunities to broaden the use of the Sentinel data infrastructure for other public health research purposes. Specific activities include guidance and facilitation of stakeholder input, technical direction and advice on the research data infrastructure needs and partnerships, contribution to the transition of the Observational Medical Outcomes Partnership (OMOP) into IMEDS and strategy for alignment and collaboration with the FDA's Sentinel Initiative pilot project (Mini-Sentinel).

Anthem Inc./HealthCore Inc., Wilmington, DE

9/2002 – 11/2011

Vice President, Government and Academic Research

3/2011 – 11/2011

Executive Director, Government and Academic Research

6/2010 – 3/2011

Served as a member of the HealthCore (research-focused subsidiary of Anthem, Inc.) senior leadership team. Responsible for the conceptualization, growth, and leadership of the Government and Academic Research (GAR) division that provides research services to the federal and state governments as well as in partnership with academic institutions. Led business development efforts including building formal strategic relationships with well-known academic institutions and federal-level grant development and submission. Served as Scientific Lead/Principal Investigator on large, multi-year research studies that incorporated integration of medical and pharmacy administrative claims data from multiple health plans linked with additional clinical data elements, including electronic medical records, registries, and electronic laboratory results. Developed and managed the GAR strategic direction, financial performance goals and objectives, and value proposition back to Anthem, including all resource requirements and the profit and loss (P & L) statement.

Highlights

- Principal Investigator for HealthCore/Anthem on the FDA 'Mini-Sentinel' consortium led by Harvard Pilgrim Healthcare and FDA
- Principal Investigator on base contract and five active ongoing task orders with the Center for Biologics Evaluation and Research (CBER), FDA
- Principal Investigator on base contract with the Center for Drug Evaluation and Research (CDER), FDA
- Led development and submission of multiple large comparative effectiveness research grants for National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ)
- Designed and lead research in the areas of pharmaceutical economics, comparative effectiveness, pharmaceutical, biologic, and vaccine safety

Director, Research Operations

5/2006 – 6/2010

Directed teams of researchers and led business development efforts for clients within the pharmaceutical and biotechnology industry. Designed research studies that integrated medical and pharmacy administrative claims data, linked with external clinical data to support outcomes research messaging for the pharmaceutical industry. Built long standing collaborations with key clients to develop research in support of outcomes and payer strategies. Led project conceptualization, proposal development, study design, defense of presentations, project planning, management, and execution for all research activities. Designed and led research in the areas of

pharmaceutical economics, outcomes research, comparative effectiveness, as well as drug, biologic, and vaccine safety.

Analytics Manager/ Outcomes Research Manager

9/2002 – 5/2006

Coordinated and managed project teams to conduct health outcomes and pharmaceutical economics research projects. Performed the roles of project manager, senior research analyst, and research analyst. Developed expertise in using administrative claims data, medical chart data, electronic laboratory result data, and surveys to conduct health outcomes research. Demonstrated expertise in the following statistical analysis techniques: parametric and non-parametric statistics, multivariable linear, logistic, multinomial, Poisson regression, Cox proportional hazards regression, generalized estimating equations (GEE), generalized linear models (GLMs), propensity score matching, covariate matching, robust variance estimation. Designed and conducted research using the following designs: retrospective cohort, prospective cohort, case-control, nested case-control, cross-sectional survey, medical record validation. Received Impact Award for successfully implementing and presenting a “best practices” presentation of using SAS and Stata to perform a Propensity Score Matching for a retrospective cohort study design. Designed and implemented clinical predictive models in chemotherapy-induced anemia and neutropenia to advance the treatment patterns for oncology patients.

Big Bear Supermarkets, Columbus Ohio

2001 – 2002

Pharmacist

Rite Aid Corporation, Columbus, Ohio

2000 – 2001

Pharmacist

EDUCATION:

Doctor of Philosophy (Ph.D.), Major in Pharmaceutical Economics, Policy, and Outcomes, Minor in Epidemiology, 2008
The University of Arizona, Tucson, Arizona

Master of Public Health (M.P.H.), Concentration in Biostatistics, 2002
The Ohio State University, Columbus, OH

Master of Science (M.S.), Major in Pharmaceutical Administration, 2001
The Ohio State University, Columbus, OH

Bachelor of Science (B.S.), Major in Pharmacy, Cum Laude, with Honors and Distinction, 2000
The Ohio State University, Columbus, OH

PEER-REVIEWED PUBLICATIONS:

Daniel GW, Cazé A, Romine MH, Audibert C, Leff JS, McClellan MB. Improving Pharmaceutical Innovation By Building A More Comprehensive Database On Drug Development And Use. *Health Affairs*. 2015; 34(2).

Outterson K, Powers JH, Daniel GW, McClellan MB. Repairing The Broken Market For Antibiotics Innovation. *Health Affairs*. 2015; 34(2).

Daniel GW, Rubens EK, McClellan M. Coverage With Evidence Development for Medicare Beneficiaries: Challenges and Next Steps. *JAMA Intern Med*. 2013 May 6:1-2.

G Sridhar, M Menis, N Selvam, L Holness, S Anderson, A Wallace, P Clark, G Daniel, R Ball, H Izurieta. Transfusion-Related Acute Lung Injury (TRALI) Occurrence, Risk Factors, and Outcome: A Nested Case-C. *The Internet Journal of Hematology*. 2013 Volume 9 Number 1.

- Schelleman H, Bilker WB, Kimmel SE, Daniel GW, Newcomb C, Guevara JP, Cziraky MJ, Strom BL, Hennessy S. Amphetamines, atomoxetine and the risk of serious cardiovascular events in adults. *PLoS One*. 2013; 8(1):e52991.
- Schneeweiss S, Rassen JA, Glynn RJ, Myers J, Daniel GW, Singer J, Solomon DH, Kim SY, Rothman KJ, Liu J, Avorn J. Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. *BMC Medical Research Methodology*. 2012, 12:180.
- Brookhart MA, Walker AM, Lu Y, Polakowski L, Li J, Paeglow C, Puenpatom T, Izurieta H, Daniel GW. Characterizing vaccine-associated risks using cubic smoothing splines. *American Journal of Epidemiology* 2012 Nov 15;176(10):949-57.
- Cutrona SL, Toh S, Iyer A, Foy S, Daniel GW, Nair VP, Daniel N, Butler MG, Boudreau D, Forrow S, Goldberg R, Gore J, McManus D, Racoosin JA, Gurwitz JH. Validation of Acute Myocardial Infarction in the Food and Drug Administration's Mini-Sentinel Program. *Pharmacoepidemiol Drug Saf*. 2013 Jan;22(1):40-54.
- Ligibel JA, O'Malley AJ, Fisher M, Daniel GW, Winer EP, Keating NL. Patterns of bone density evaluation in a community population treated with aromatase inhibitors. *Breast Cancer Res Treat*. 2012 Aug;134(3):1305-13.
- Eisenberg DF, Daniel GW, Jones JK, Goehring EL Jr, Wahl PM, Winters P, Levin J, Bohn RL. Validation of a claims-based diagnostic code for Stevens-Johnson syndrome in a commercially insured population. *Pharmacoepidemiology and Drug Safety*. 2012 Jul;21(7):760-764.
- Daniel GW, Menis M, Sridhar G, Wallace A, Golding B, Anderson S, Epstein J, Martin D, Ball R, Izurieta H. Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010. *Transfusion*. 2012 Oct;52(10):2113-21
- Gagne JJ, Glynn RJ, Rassen JA, Walker AM, Daniel GW, Sridhar G, Schneeweiss S. Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system. *Clinical Pharmacology and Therapeutics*. 2012 Jul;92(1):80-6.
- Wahl PM, Gagne JJ, Wasser TE, Eisenberg DF, Rodgers JK, Daniel GW, Wilson M, Schneeweiss S, Rassen JA, Patrick AR, Avorn JA, Bohn RL. Early steps in development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples. *Drug Safety* 2012 May 1;35(5):407-16.
- Schelleman H, Bilker WB, Kimmel SE, Daniel GW, Newcomb C, Guevara JP, Cziraky MJ, Strom BL, Hennessy S. Methylphenidate and risk of serious cardiovascular events in adults. *Am J Psychiatry*. 2012 Feb 1;169(2):178-85.
- Curtis LH, Weiner MG, Boudreau DM, Cooper WO, Daniel GW, Nair VP, Raebel MA, Beaulieu NU, Rosofsky R, Woodworth TS, and Brown JS. (2012), Design considerations, architecture, and use of the Mini-Sentinel distributed data system. *Pharmacoepidemiology and Drug Safety*. 2012 Jan;21 Suppl 1:23-31
- Fireman B, Toh S, Butler MG, Go AS, Joffe HV, Graham DJ, Nelson JC, Daniel GW, and Selby JV. (2012), A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent. *Pharmacoepidemiology and Drug Safety*. 2012 Jan;21 Suppl 1:282-90.
- Munson JC, Wahl PM, Daniel G, Kimmel SE, Hennessy S. Factors associated with the initiation of proton pump inhibitors in corticosteroid users. *Pharmacoepidemiology and Drug Safety*. 2012 Apr;21(4):366-74.
- Kim SY, Solomon DH, Liu J, Chang G, Daniel GW, Schneeweiss S. Accuracy of identifying neutropenia diagnoses in outpatient claims data. *Pharmacoepidemiology and Drug Safety*. 2011 Jul;20(7):709-13.
- Schelleman H, Bilker WB, Strom BL, Kimmel SE, Newcomb C, Guevara JP, Daniel GW, Cziraky J, Hennessy S. Cardiovascular events and death in children exposed and unexposed to ADHD agents. *Pediatrics*. 2011 Jun;127(6):1102-10.

Ligibel, JA, O'Malley AJ, Fisher M, Daniel GW, Winer EP, Keating NL. Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients. *Breast Cancer Research and Treatment*. *Breast Cancer Res Treat*. 2012 Jan;131(2):589-97.

Kuriya B, Hernández-Díaz S, Liu J, Bermas BL, Daniel G, Solomon DH. Patterns of Drug Use During Pregnancy in Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)*. 2011 May;63(5):721-8.

Tan H, Tomic K, Hurley D, Daniel G, Barron R, Malin J. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study. *Curr Med Res Opin*. 2011 Jan;27(1):79-86.

Kim SY, Schneeweiss S, Liu J, Daniel GW, Chang G, Garneau K, Solomon DH. Risk of osteoporotic fracture in a large population-based cohort study of patients with rheumatoid arthritis. *Arthritis Research & Therapy*. 2010;12(4):R154.

Daniel GW, Ewen E, Willey VJ, Reese CL, Shirazi FM, Malone DC. Efficiency and economic benefits of a payer-based electronic health record in an emergency department. *Academic Emergency Medicine*. 2010; Aug 17(8):824-833.

Croghan TW, Esposito D, Daniel G, Wahl P, Stoto MA. Using medical records to supplement a claims-based comparative effectiveness analysis of antidepressants. *Pharmacoepidemiology and Drug Safety*. 2010;19: 814-818.

Brophy D, Daniel G, Gitlin M, Mayne TJ. Characterizing hospitalizations of end-stage renal disease patients on dialysis and inpatient utilization of erythropoiesis stimulating agent therapy. *Annals of Pharmacotherapy*. 2010 Jan;44(1):43-9.

Hennessy S, Schelleman H, Daniel GW, Bilker WB, Kimmel SE, Guevara J, Cziraky J, Strom, BL. Cardiovascular Safety of Attention Deficit Hyperactivity Disorder Medications: Rationale for and Design of an Investigator-Initiated Observational Study. *Pharmacoepidemiology and Drug Safety*. 2010; Sep 19(9):934-41.

Daniel GW, Hurley D, Whyte J, Willey VJ, Wilson M, Kallich J. Use and cost of erythropoiesis- stimulating agents in patients with cancer. *Curr Med Res Opin*. 2009;25(7):1775–1784.

Esposito D, Wahl P, Daniel GW, Stoto MA, Erder HM, Croghan TW. Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States. *Clinical Therapeutics*. 2009;31(3):644-656.

Barron JJ, Daniel GW, Makin C, Preblich R, Lau H. Treatment modifications, healthcare resource utilization, and costs associated with fixed-dose and free-agent ACE inhibitor and calcium channel blocker combination antihypertensive regimens. *Drug Benefit Trends*. 2008; 20:226-247.

Daniel GW, Malone DC. Characteristics of older adults who meet the annual prescription drug expenditure threshold for Medicare medication therapy management programs. *J Manag Care Pharm*. 2007;13(2):42-54.

Nag SS, Daniel GW, Bullano MF, Kamal-Bahl S, Sajjan SG, Hu HX, Alexander C. LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO. *J Manag Care Pharm*. 2007;13(8):652-663.

BOOK CHAPTERS:

Seeger J and Daniel GW. Commercial insurance databases. In Strom BL, Kimmel SE, Hennessy S, eds. *Pharmacoepidemiology*. 5th ed. Hoboken, NJ: Wiley-Blackwell; 2012:189.

ABSTRACT PRESENTATIONS:

Elisabetta Paterno, Rhonda Bohn, Peter Wahl, Gregory Daniel, Jerry Avorn, Jun Liu, Helen Mogun, Sebastian Schneeweiss. Risk of Coronary Events and Stroke in Patients Taking Anticonvulsant Medications. Podium

presentation presented at the International Society for Pharmacoepidemiology (ISPE) 27th Anniversary International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE). Chicago, August 2011.

Jeffrey C Munson, Peter M Wahl, Gregory Daniel, Stephen E Kimmel, Sean Hennessy. Proton Pump Inhibitors and Fracture Risk in Corticosteroid Users. Podium presentation presented at the International Society for Pharmacoepidemiology (ISPE) 27th Anniversary International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE). Chicago, August 2011.

Daniel GW, Menis M, Wallace AE, Sridhar G, Izurieta H. Identification of adverse events after immunoglobulin exposure: Exploratory analysis of administrative claims data. Poster presentation presented at the International Society for Pharmacoepidemiology (ISPE) 27th Anniversary International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE). Chicago, August 2011.

Paeglow CE, Daniel GW, Polakowski L Brookhart A, Lu Y, Li J, Puenpatom T, Izurieta H, Walker A. Hypothesis Generating Self-Controlled Analysis: Example in Childhood Vaccine Safety. Poster presentation presented at the International Society for Pharmacoepidemiology (ISPE) 27th Anniversary International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE). Chicago, August 2011.

Polakowski L, Li J, Daniel GW, Paeglow C, Puenpatom T, Lu Y, Walker A, Brookhart MA, Izurieta H. Temporal trends in health care utilization among 1-year old vaccines: an example of study design refinement for use in vaccine safety surveillance. Poster presentation presented at the International Society for Pharmacoepidemiology (ISPE) 27th Anniversary International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE). Chicago, August 2011.

Sridhar G, Menis M, Wallace AE, Daniel GW, Izurieta H. Immunoglobulin use and thromboembolic events. Poster presentation presented at the International Society for Pharmacoepidemiology (ISPE) 27th Anniversary International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE). Chicago, August 2011.

Walker AM, Puenpatom T, Li J, Daniel GW, Brookhart MA, Polakowski L, Lu Y, Izurieta H. Search for new safety signals in the patterns of care following MMR vaccine. Poster presentation presented at the International Society for Pharmacoepidemiology (ISPE) 27th Anniversary International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE). Chicago, August 2011.

Brookhart MA, Li J, Paeglow C, Puenpatom T, Polakowski L, Lu Y, Walker AM, Izurieta H, Daniel GW. Characterizing vaccine-associated risk using natural smoothing splines. Podium presentation presented at the International Society for Pharmacoepidemiology (ISPE) 27th Anniversary International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE). Chicago, August 2011.

Li J, Daniel GW, Paeglow C, Puenpatom T, Polakowski L, Lu Y, Walker AM, Brookhart MA, Izurieta H. Use of the Self-Controlled Risk Interval Design in Childhood Vaccine Safety. Podium presentation presented at the International Society for Pharmacoepidemiology (ISPE) 27th Anniversary International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE). Chicago, August 2011.

Hedi Schelleman, Warren B Bilker, Stephen E Kimmel, Gregory W Daniel, Craig Newcomb, James P Guevara, Mark J Cziraky, Brian L Strom, Sean Hennessy. ADHD Medications and Risk of Serious Cardiovascular Events in Adults. Podium presentation presented at the International Society for Pharmacoepidemiology (ISPE) 27th Anniversary International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE). Chicago, August 2011.

Alexander M Walker, Gregory W Daniel, Karen Smoyer-Tomic, Tosmai Puenpatom, Tao Gu, Hector Izurieta. Identification of Novel Post-Vaccine Syndromes Using Information Theory [16]. Podium presentation presented at the International Society for Pharmacoepidemiology (ISPE) 26th Anniversary International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE). Brighton, England, UK, August 20, 2010 9:45am.

S Schneeweiss, JA Rassen, J Avorn, DH, Solomon, SY Kim, G Daniel, KJ Rothman, J Liu, RJ Glynn. Using Laboratory Data To Supplement Claims Data To Improve Control of Confounding in Studies of Treatment Effects [89]. Using Laboratory Data To Supplement Claims Data To Improve Control of Confounding in Studies of Treatment Effects [89]. Poster presented at the International Society for Pharmacoepidemiology (ISPE) 26th Anniversary International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE). Brighton, England, UK, August 19-22, 2010.

Kim SY, Solomon DH, Liu J, Chang G, Daniel GW, Schneeweiss S. Accuracy of Identifying Outpatient Neutropenia Diagnoses in Claims Data [174]. Poster presented at the International Society for Pharmacoepidemiology (ISPE) 26th Anniversary International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE). Brighton, England, UK, August 19-22, 2010.

Munson JC, Wahl PM, Daniel GW, Kimmel SE, Hennessy S. Factors Associated with the Initiation of Proton Pump Inhibitors in New Corticosteroid Users [387]. Poster presented at the International Society for Pharmacoepidemiology (ISPE) 26th Anniversary International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE). Brighton, England, UK, August 19-22, 2010.

Daniel GW, Eisenberg DF, Jones JK, Goehring EL, Winters P, Levin J, Wahl PM, Bohn RL. Validation of a Claims-Based Diagnostic Code for Stevens-Johnson Syndrome (SJS) in a Commercially-Insured Population. Poster presented at the International Society for Pharmacoepidemiology (ISPE) 26th Anniversary International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE). Brighton, England, UK, August 19-22, 2010. *Award Winner: Third Place.*

Eisenberg DF, Daniel GW, Subramanian U, Breen T, Bohn RL, Wahl PM, Herman WH. Validation of Claims-Based Diagnostic Codes for Severe Hypoglycemic Events (SHEs) in a Commercially-Insured Population. Poster presented at the International Society for Pharmacoepidemiology (ISPE) 26th Anniversary International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE). Brighton, England, UK, August 19-22, 2010.

Wahl PM, Paeglow CE, Gu T, Wilson M, Daniel GW. Characteristics of H1N1 Vaccine Exposures in a Large Commercially Insured Population. Poster presented at the International Society for Pharmacoepidemiology (ISPE) 26th Anniversary International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE). Brighton, England, UK, August 19-22, 2010.

Wahl PM, Gagne J, Wasser T, Eisenberg DF, Rodgers K, Daniel GW, Wilson MD, Schneeweiss S, Rassen JA, Patrick AR, Avorn J, Bohn RL. Development of a Claims-Based Healthcare Safety Sentinel System Featuring Signal Strengthening During Sequential Monitoring. Poster presented at the International Society for Pharmacoepidemiology (ISPE) 26th Anniversary International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE). Brighton, England, UK, August 19-22, 2010.

Daniel GW, Ewen E, Willey VJ, Shirazi F, Malone, DC. Efficiency and Economic Benefits Associated with the Use of a Payer-based Electronic Health Record in an Emergency Department among a Health Insured Population. Podium presented at the International Society for Pharmacoeconomics and Outcomes Research 14th Annual International Meeting, May 19, 2009.

Rosenman MB, Wahl PM, Daniel G, Overhage JM, McGuire P, Thompson D, Rodgers K, Short L, Bohn R, Tierney WM. Electronic Medical Records System Validation of Claims-Based Queries for Acute Kidney Injury. Poster presented at the National Kidney Foundation (NKF) Spring Clinical Meeting. Nashville, TN, March 25, 2009.

Esposito D, Wahl P, Daniel G, Stoto MA, Erder MH, Croghan TW. Initiating treatment on generic antidepressants may not save healthcare costs. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research 13th Annual International Meeting, May 5, 2008.

Brophy D, Harley C, Chastek B, Daniel G, McNeeley B, Gitlin M, Mayne T. Inpatient use of erythropoiesis-stimulating agents among commercially insured dialysis patients. Poster presentation at the National Kidney Foundation Spring Clinical Meetings, March 2008.

Brophy D, Daniel G, McNeeley B, Gitlin M, Mayne T. Majority of dialysis patients do not receive erythropoiesis-stimulating agents during hospitalization. Poster presentation at the American Society of Health-System Pharmacists Summer Meeting, June 2007.

Daniel G, Gitlin M, McNeeley B, Kim J, Mayne T. The cost of treating end-stage renal disease within a managed care organization. Poster presentation at the Academy of Managed Care Pharmacy Educational Conference, 2007.

Daniel G, Gitlin M, McNeeley B, Kim J, Mayne T. Comparison of Medicare and commercial treatment costs for end-stage renal disease patients. Poster presentation at the American Society of Nephrology conference, 2007.

Daniel GW, Hurley D, Whyte J, Grochulski WD, Willey VJ, Kallich J. Analysis of Dose, Cost and Use Patterns of Erythropoietin Stimulating Agents in Cancer Patients. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research 12th Annual International Meeting, May 22, 2007.

Makin C, Barron J, Daniel G, Preblich R, Lau H. Impact of Antihypertensive Therapy Modifications on Hypertension & Cardiovascular-Related Costs. Poster presentation at Academy of Managed Care Pharmacy 19th Annual Meeting, April 11-14, 2007.

Makin c, Barron J, Daniel G, Preblich R, Lau H. Treatment Patterns, Healthcare Resource Utilization & Costs Associated with the Use of Combination Antihypertensive Regimens in Hypertension. Poster presentation at Academy of Managed Care Pharmacy 19th Annual Meeting, April 11-14, 2007.

Daniel GW, Malone DC. Characteristics of seniors with high annual prescription drug expenditures: Findings from the 2002 and 2003 Medical Expenditure Panel Survey. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research 11th Annual International Meeting, Philadelphia, PA, May 20-24, 2006.

Daniel GW, Nag SS, Bullano MF, Kamal Bahl SJ, Sajjan S, Hu H, Alexander CM. Lipid Treatment and LDL-C Goal Attainment Among High Risk Patients in a Managed Care Setting. Poster accepted at Academy of managed Care Pharmacy 18th Annual Meeting, April 5-8, 2006. (Accepted)

Daniel G, Kamat S, Brewer K, Bullano M, Telly T, Williamson T. Selected outcomes in patients with overactive bladder compared to non-overactive bladder controls. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 10th Annual International Meeting, Washington (DC), May 15-18, 2005. *Value in Health*. 2005; 8(3):413.

Daniel G, Kamat S, Brewer K, Bullano M, Telly T, Williamson T. Prevalence, demographics, and pharmacological treatment patterns of overactive bladder in a managed care population. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 10th Annual International Meeting, Washington (DC), May 15-18, 2005. *Value in Health*. 2005; 8(3):418.

Alexander CM, Kamal-Bahl SJ, Nag S, Cziraky MJ, Willey VJ, Foley KA, Daniel GW, Sajjan S, Bullano MF. Disparity between non-HDL goal attainment and National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) recommendations. Poster presented at the American Heart Association's 5th Scientific Forum of Quality of Care and Outcomes Research, Washington (DC), May 15-17, 2004.

Daniel G, Bullano MF, Nag S, Kamal-Bahl SJ, Foley K, Sajjan S, Willey V, Cziraky M, Alexander C. Assessment of lipid-lowering treatment and LDL-C goal attainment within a managed care population newly diagnosed with coronary heart disease or diabetes mellitus. Poster presented at the American Heart Association's 5th Scientific Forum of Quality of Care and Outcomes Research, Washington (DC), May 15-17, 2004.

Barron JJ, Lawless GD, Willey VJ, Tannous RE, Daniel GW. Hemoglobin levels associated with diagnosis of anemia. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 6th European Congress, Barcelona (Spain), November 2003.

Lawless GD, Daniel GW, Barron JJ, Tannous RE, Willey VJ. Probability of initiating erythropoietic therapy. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 6th European Congress, Barcelona (Spain), November 2003.

Hoffman L, Pippins J, Bullano MF, Barron JJ, Daniel G, Mayzell G. Impact of risk modeling information on the prescribing of COX-2 inhibitor agents. Poster presentation at the ISPOR Annual International Meeting, Arlington (VA), May 2003.

PROFESSIONAL MEETING PRESENTATIONS:

“Electronic Health Records and Meaningful Use: Opportunities for Evolution in Comparative Effectiveness Research.” Gregory W. Daniel, PhD, RPh, MPH, Jane Griffin, RPh, Eugene Rich, MD, Rolin Wade, RPh, MS. Workshop presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 26th Annual International Meeting, Baltimore, MD, May 25, 2011.

“Understand and Reduce Bias in Data.” Workshop lead for pre-conference workshop for The Center for Business Intelligence (CBI) Bio/Pharmaceutical Forum on Optimizing the Use of Secondary Data Sources, Philadelphia, PA, January 21, 2010.

“MTM: Who Qualifies?” An overview of the Medication Therapy Management (MTM) requirements under the Medicare Modernization Act of 2003. Also presented were the methods and results of an examination of the characteristics of seniors who would qualify for MTM services using data from a nationally representative survey. Presented at the Center for Health Outcomes & Pharmacoeconomic Research 14th Annual Invitational Conference, Tucson, Arizona, January 2006.

“Development of a Predictive Model Tool: Chemotherapy-Induced Neutropenia.” A discussion of the research methods, results and implications of a clinical predictive model designed to identify cancer patients at high risk for severe neutropenia. Presented at the Managed Care Network (MCN) Meeting, New York City, December 2004.

LICENSURE:

Registered Pharmacist, State of Ohio

PROFESSIONAL AFFILIATIONS AND MEMBERSHIPS:

2000-present	International Society for Pharmacoeconomics and Outcomes Research
2002-present	Academy of Managed Care Pharmacy
2007-present	International Society for Pharmacoepidemiology and Drug Safety
2007-present	International Society for Pharmacoepidemiology
2012-present	Advisory Board, B.R.I.D.G.E. TO DATA®
2013-present	Editorial Advisory Board, Therapeutic Innovation & Regulatory Science
2007-2014	Editorial Advisory Board, Journal of Managed Care Pharmacy

HONORS AND AWARDS:

2009	Best Podium Presentation, 2009 ISPOR 14th Annual International Meeting
2009	Anthem/HealthCore Impact Award
2006	Fellow, American Foundation for Pharmaceutical Education
2004	Anthem/HealthCore Impact Award
2001	Fellow, Procter & Gamble

2000 Rho Chi Pharmacy Honor Society induction
2000 Phi Lambda Sigma Pharmacy Leadership Society induction
1999 Intern of the Year- Ohio Society of Health System Pharmacists
1999 Intern of the Year- Central Ohio Society of Health System Pharmacists